Veracyte follows IPO with massive Dx revenue growth

Veracyte CEO Bonnie Anderson

Veracyte ($VCYT) released its first quarterly earnings report as a public company this week. The molecular diagnostics company has a lot to celebrate. Revenue reached $5.6 million for the 2013 third quarter, up 74% from $3.2 million booked over the same period a year ago. Much wider adoption of the California company's Afirma Thyroid FNA Analysis test helped drive the increase. Veracyte's CLIA-certified lab processed 12,417 FNA samples during the quarter, versus 7,052 in the third quarter of 2012. Net losses reached $6.3 million, up from $4.9 million in the 2012 third quarter--a number that reflects an expanded commercial ramp-up. The Afirma test combines a specialized cytopathology assessment and a gene-expression test to determine whether a thyroid nodule is benign or cancerous. "In the near term we are really focused on diving growth at the top line and expanding our portfolio beyond the thyroid product to include other indications," CEO Bonnie Anderson told FierceDiagnostics. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.